Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 134.15
ATOS's Cash to Debt is ranked higher than
68% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.28 vs. ATOS: 134.15 )
Ranked among companies with meaningful Cash to Debt only.
ATOS' s 10-Year Cash to Debt Range
Min: 0.05  Med: 265.26 Max: No Debt
Current: 134.15
Equity to Asset 0.79
ATOS's Equity to Asset is ranked higher than
76% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. ATOS: 0.79 )
Ranked among companies with meaningful Equity to Asset only.
ATOS' s 10-Year Equity to Asset Range
Min: -0.66  Med: 0.79 Max: 0.95
Current: 0.79
-0.66
0.95
F-Score: 4
Z-Score: -1.25
M-Score: 23.02
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -306.84
ATOS's Operating margin (%) is ranked lower than
85% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. ATOS: -306.84 )
Ranked among companies with meaningful Operating margin (%) only.
ATOS' s 10-Year Operating margin (%) Range
Min: -171450  Med: -2243.72 Max: -1051.66
Current: -306.84
-171450
-1051.66
Net-margin (%) -307.14
ATOS's Net-margin (%) is ranked lower than
85% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.79 vs. ATOS: -307.14 )
Ranked among companies with meaningful Net-margin (%) only.
ATOS' s 10-Year Net-margin (%) Range
Min: -172100  Med: -2245.24 Max: -1053.94
Current: -307.14
-172100
-1053.94
ROE (%) -117.01
ATOS's ROE (%) is ranked lower than
83% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.52 vs. ATOS: -117.01 )
Ranked among companies with meaningful ROE (%) only.
ATOS' s 10-Year ROE (%) Range
Min: -972.32  Med: -148.34 Max: -136.71
Current: -117.01
-972.32
-136.71
ROA (%) -98.69
ATOS's ROA (%) is ranked lower than
86% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.05 vs. ATOS: -98.69 )
Ranked among companies with meaningful ROA (%) only.
ATOS' s 10-Year ROA (%) Range
Min: -223  Med: -118.92 Max: -102.65
Current: -98.69
-223
-102.65
ROC (Joel Greenblatt) (%) -5510.62
ATOS's ROC (Joel Greenblatt) (%) is ranked lower than
95% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.58 vs. ATOS: -5510.62 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ATOS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6677.4  Med: -3477.21 Max: -1141.33
Current: -5510.62
-6677.4
-1141.33
» ATOS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ATOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.70
ATOS's P/B is ranked higher than
74% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.33 vs. ATOS: 1.70 )
Ranked among companies with meaningful P/B only.
ATOS' s 10-Year P/B Range
Min: 1.03  Med: 3.80 Max: 22.55
Current: 1.7
1.03
22.55
P/S 3.83
ATOS's P/S is ranked lower than
60% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.99 vs. ATOS: 3.83 )
Ranked among companies with meaningful P/S only.
ATOS' s 10-Year P/S Range
Min: 3.58  Med: 80.34 Max: 221
Current: 3.83
3.58
221
Current Ratio 4.03
ATOS's Current Ratio is ranked higher than
69% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.49 vs. ATOS: 4.03 )
Ranked among companies with meaningful Current Ratio only.
ATOS' s 10-Year Current Ratio Range
Min: 0.01  Med: 2.89 Max: 16.36
Current: 4.03
0.01
16.36
Quick Ratio 4.00
ATOS's Quick Ratio is ranked higher than
72% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. ATOS: 4.00 )
Ranked among companies with meaningful Quick Ratio only.
ATOS' s 10-Year Quick Ratio Range
Min: 0.01  Med: 2.89 Max: 16.36
Current: 4
0.01
16.36
Days Inventory 6.09
ATOS's Days Inventory is ranked higher than
95% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.75 vs. ATOS: 6.09 )
Ranked among companies with meaningful Days Inventory only.
ATOS' s 10-Year Days Inventory Range
Min: 21.41  Med: 21.41 Max: 21.41
Current: 6.09
Days Sales Outstanding 145.16
ATOS's Days Sales Outstanding is ranked lower than
92% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.30 vs. ATOS: 145.16 )
Ranked among companies with meaningful Days Sales Outstanding only.
ATOS' s 10-Year Days Sales Outstanding Range
Min: 80.15  Med: 145.02 Max: 206.79
Current: 145.16
80.15
206.79

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.85
ATOS's Price/Net Cash is ranked higher than
85% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.50 vs. ATOS: 2.85 )
Ranked among companies with meaningful Price/Net Cash only.
ATOS' s 10-Year Price/Net Cash Range
Min: 2.68  Med: 6.61 Max: 390
Current: 2.85
2.68
390
Price/Net Current Asset Value 2.14
ATOS's Price/Net Current Asset Value is ranked higher than
86% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.45 vs. ATOS: 2.14 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ATOS' s 10-Year Price/Net Current Asset Value Range
Min: 2.49  Med: 5.81 Max: 130
Current: 2.14
2.49
130
Price/Tangible Book 1.97
ATOS's Price/Tangible Book is ranked higher than
78% of the 145 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.76 vs. ATOS: 1.97 )
Ranked among companies with meaningful Price/Tangible Book only.
ATOS' s 10-Year Price/Tangible Book Range
Min: 2.45  Med: 5.45 Max: 97.5
Current: 1.97
2.45
97.5
Price/Median PS Value 0.05
ATOS's Price/Median PS Value is ranked higher than
97% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. ATOS: 0.05 )
Ranked among companies with meaningful Price/Median PS Value only.
ATOS' s 10-Year Price/Median PS Value Range
Min: 0.07  Med: 1.04 Max: 2.16
Current: 0.05
0.07
2.16
Earnings Yield (Greenblatt) (%) -140.88
ATOS's Earnings Yield (Greenblatt) (%) is ranked lower than
96% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.40 vs. ATOS: -140.88 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ATOS' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -162.18  Med: 0.00 Max: 0
Current: -140.88
-162.18
0

Analyst Estimate

Dec15
Revenue(Mil) 8
EPS($) -0.33
EPS without NRI($) -0.33

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:YAG.Germany,
Atossa Genetics Inc was incorporated in Delaware on April 2009. The Company is a healthcare company, engaged in the improvement of breast health through the development of a suite of laboratory developed tests (LDTs), FDA cleared medical devices and therapeutics. Its laboratory tests are being developed by its subsidiary, The National Reference Laboratory for Breast Health, Inc. (the NRLBH), and are intended to address each of the four stages of the breast health care path: the cytological analysis of nipple aspirate fluid (NAF); the cytological analysis of ductal lavage fluid collected from each individual breast duct with its proprietary microcatheters; the profiling of newly diagnosed breast cancers through the determination of gene expression profiles in breast cancer biopsy tissue; and the monitoring of breast cancer survivors for pre-clinical recurrence through a blood test for circulating tumor cells. The Company's medical devices under development include the ForeCYTE Breast Aspirator (510(k) pending, not for sale in the United States) intended for the collection of NAF for cytological testing at a laboratory, intra ductal microcatheters for the collection of ductal lavage fluid and for the potential administration of a targeted therapeutic, and various tools for potential use by breast surgeons. It owns 137 issued patents (45 in the United States and at least 92 in foreign countries), and 11 pending patent applications (9 in the United States and 2 pending International Patent Cooperation Treaty (PCT) application) directed to its products, services, and technologies. The Federal Food, Drug, and Cosmetic Act, or FDCA, and the FDA's implementing regulations, govern registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, and post-market surveillance. Medical devices and the manufacturers are also subject to inspection by the FDA. The FDCA, supplemented by other federal and state laws, also provides civil and criminal penalties for violations of its provisions.
» More Articles for ATOS

Headlines

Articles On GuruFocus.com
Atossa Genetics Subsidiary The NRLBH Now Provides Enhanced Pharmacogenetic Test Based on Luminex xTA Jul 22 2015 
Atossa Genetics Announces Acquisition of Ductal Lavage Specimen Bank From the Dr. Susan Love Researc Jul 01 2015 
Atossa Genetics (ATOS) Soars on Distribution Deal, Conn's (CONN) Rating Boosted Feb 09 2015 
Atossa Genetics Announces the Publication of: Proliferative Epithelial Disease Identified in Nipple Jan 19 2015 
Atossa Genetics to Present at Upcoming Investor Conferences in January 2015 Jan 06 2015 
Atossa Genetics Inc. Provides Update on Pharmacogenetics Testing Now Offered by The National Referen Dec 19 2014 
Atossa Genetics Inc. Hires Pieter van der Poel as Vice President of European Commercial Operations Dec 16 2014 
Atossa Genetics Inc. Announces Successful Closure of FDA Inspections Dec 05 2014 
Atossa Genetics Inc. Announces Contract With Rhenus Advanced Services B.V. Dec 02 2014 
Atossa Genetics to Announce Third Quarter 2014 Financial Results and Provide a Company Update on Wed Nov 07 2014 

More From Other Websites
Edited Transcript of ATOS earnings conference call or presentation 6-Aug-15 8:30pm GMT Aug 26 2015
ATOSSA GENETICS INC Financials Aug 19 2015
ATOSSA GENETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 06 2015
Atossa Genetics Announces Second Quarter 2015 Financial Results and Provides Company Update;... Aug 06 2015
Atossa Genetics and AAIPharma / Cambridge Major Laboratories Announce Manufacturing Agreement For... Aug 06 2015
Q2 2015 Atossa Genetics Inc Earnings Release - After Market Close Aug 06 2015
Atossa Genetics to Announce Second Quarter 2015 Financial Results and Provide a Company Update on... Aug 05 2015
Atossa Genetics and AAIPharma / Cambridge Major Laboratories Announce Manufacturing Agreement for... Aug 05 2015
Atossa Genetics Subsidiary The NRLBH Now Provides Enhanced Pharmacogenetic Test Based on Luminex... Jul 22 2015
Atossa Genetics Announces Acquisition of Ductal Lavage Specimen Bank From the Dr. Susan Love... Jul 01 2015
Atossa Genetics (ATOS) Stock Gains After Receiving Breast Cancer Detection Patent Jun 11 2015
Atossa Genetics Announces Issuance of Patent US9,052,318 by the U.S. Patent and Trademark for Breast... Jun 11 2015
ATOSSA GENETICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement Jun 10 2015
Atossa Genetics Inc. to Raise Approximately $6,220,000 From Institutional Healthcare Investors Jun 05 2015
ATOSSA GENETICS INC Files SEC form 8-K, Change in Directors or Principal Officers Jun 04 2015
Atossa Genetics to Present at the LD Micro Invitational Conference on Tuesday, June 2, 2015 May 29 2015
ATOSSA GENETICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a... May 28 2015
Atossa Genetics Announces $25 Million At-the-Market Common Stock Purchase Agreement With Aspire... May 28 2015
Atossa Genetics Hires Dr. Gerald Engley as Senior Director of Medical Affairs May 27 2015
ATOS: Atossa Enters into Therapeutic Market May 19 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK